Barbiturates have a long history of being used as drugs. Since the first barbiturate, Veronal, was marketed as a sleeping aid more than a century ago, barbiturates have been used as central nervous system (CNS) depressants.
1 Short-acting barbiturates are used as anesthetics and long-acting ones as antiepilepsy drugs.
2 Sodium pentothal belongs to the first class and phenobarbital to the latter class.
2 Beside the effects on the CNS, wide varieties of other biological activities have been recognized for barbiturates.
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Noteworthy among them is the inhibition of the phosphatase activity of calcineurin, a protein Ser/Thr phosphatase. 4 Recently, we reported the inhibitory activities of barbiturates against protein tyrosine phosphatase (PTP) 1B and other PTPs. 3 The study focused on the barbiturates with a substituent at C-5 of a barbituric acid core structure, and compound 1 was identified as the most potent PTP1B inhibitor among the series. Commonly used barbiturates like phenobarbital and sodium pentothal have a substituent at C-5 of this basic skeleton. In a virtual screening to find a lead compound for PTP1B inhibitor development, we previously identified barbiturates, 2 and 3, which showed IC 50 values against PTP1B of 35 µM and 12 µM, respectively. 5 Based on this result, we extended our study to the barbiturates possessing dual substituents at N-1 and C-5 of the barbituric acid core structure.
Barbituric acid derivatives were synthesized by the condensation of N-substituted barbituric acid derivatives (A) and Nsubstituted indole-3-carboxaldehyde derivatives (B) (Scheme 1). 6 An aldehyde derivative, B (0.05 mmole), was added as a solid into a solution of N-substituted barbiturate A (0.05 mmole) in dry DMF (0.1 mL) in an 1.6 mL sized Eppendorf tube. When heated at 80 ºC for 6 h and cooled to room temperature, the reaction product precipitated. The precipitate was washed with iPrOH (0.1 mL × 3) to obtain a solid product free from DMF. The products obtained in this way showed essentially a single spot in TLC analysis and were used as such for enzyme experiments without further purification steps. Using this method, multiple condensation reactions could be performed at the same time and the products could be harvested on the same day.
The precursors, A and B, for the condensation reaction were prepared as shown in Scheme 2. Briefly, N-substituted barbiturates (A) were prepared by the conversion of appropriate arylamines (D) to arylurea (E), 7 followed by condensation with malonate. 6 To prepare N-substituted indole-3-carboxaldehydes (B), indole was treated with appropriate benzylhalide or halomethylnaphthyl derivatives (F) 8 in the presence of KOH as a base.
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The first set of compounds, 3-9, was prepared with R 1 fixed as H and R 2 being varied as shown in Table 1 . These compounds were examined for their inhibitory activity against PTP1B and VHR phosphatase. IC 50 values were determined by measuring the enzyme activity at a range of different inhibitor concentrations using p-nitrophenyl phosphate (pNPP) as the substrate. Among the various substituted phenyl and naphthyl derivatives, compound 3 and 7 with a 1-naphthyl and a 1-(4-bromo)naphthyl moiety, respectively, for R 2 gave the lowest IC 50 value against PTP1B. From the two, the 1-naphthyl moiety was selected for R 2 due to its molecular weight being lower than that of the corresponding bromonaphthyl moiety. A second set of compounds 10-17 was then prepared with R 2 fixed as the 1-naphthyl moiety. Various derivatives of A were subjected to condensation reactions with 1-naphthyl-B as the counterpart. Among the compounds synthesized, 7 proved to be the most potent inhibitor of PTP1B. † This paper is dedicated to Professor Eun Lee on the occasion of his honourable retirement. The nature of inhibition by compound 7 was investigated by steady-state kinetic experiments on two human PTPs, PTP1B and VHR phosphatase, and a yeast PTP, YPTP1. PTP1B and YPTP1 are tyrosine-specific PTPs, while VHR phosphatase is classified as a tyrosine and serine/threonine dual-specificity phosphatase, which has little homology with the tyrosine-specific PTPs except at the active site region.
10
VHR phosphatase is also much smaller in size compared to the catalytic domain of PTP1B. Lineweaver-Burk plot analysis revealed that compound 7 inhibited PTP1B in a noncompetitive fashion (Figure 2a) . Noncompetitive inhibition was also observed for YPTP1 (data not shown). On the other hand, compound 7 exhibited a competitive inhibition pattern for VHR phosphatase, which indicates that the inhibitor competes with the substrate in binding on VHR phosphatase (Figure 2b ). These results from kinetic experiments suggest the binding of 7 in the active site on VHR phosphatase, but not in the active sites on PTP1B and YPTP1. However, this supposition apparently contradicts the structural diversity of the three PTPs except for at their active sites, especially between VHR phosphatase and the other PTPs. Furthermore, the nondiscriminatory inhibition of the PTPs by compound 7 implies that there exists structural similarity between the inhibitor binding sites on the three PTPs. To the best of our knowledge on the 3-dimensional structures of the PTPs, the active sites of the three PTPs are the only conceivable binding pockets for compound 7, except the secondary aryl phosphate-binding site present near the active site of PTP1B. In our previous study on monosubstituted barbiturate compounds, similarly conflicting results were obtained. Compound 1 exhibited a noncompetitive inhibition pattern for PTP1B and a mixed-type noncompetitive pattern for YPTP1. 3 The binding sites of the barbiturate derivatives on PTP1B and YPTP1 are yet to be determined through X-ray crystallographic study of the enzyme-inhibitor complex. However, in the present study, the barbiturate moiety was recognized as a scaffold for the design of active site-direct inhibitors of VHR phosphatase.
